No headlines found.
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
Globe Newswire (Wed, 9-Aug 4:05 PM ET)
ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
Globe Newswire (Wed, 2-Aug 7:00 AM ET)
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
Globe Newswire (Wed, 19-Jul 7:00 AM ET)
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Adma Biologics trades on the NASDAQ stock market under the symbol ADMA.
As of September 25, 2023, ADMA stock price declined to $3.49 with 809,062 million shares trading.
ADMA has a beta of 1.29, meaning it tends to be more sensitive to market movements. ADMA has a correlation of 0.19 to the broad based SPY ETF.
ADMA has a market cap of $784.92 million. This is considered a Small Cap stock.
Last quarter Adma Biologics reported $60 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$.01.
In the last 3 years, ADMA stock traded as high as $4.65 and as low as $1.01.
The top ETF exchange traded funds that ADMA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.
ADMA has outperformed the market in the last year with a return of +36.3%, while the SPY ETF gained +17.2%. However, in the most recent history, ADMA shares have underperformed the stock market with its stock returning -10.1% in the last 3 month period and -9.1% for the last 2 week period, while SPY has returned -0.6% and -2.6%, respectively.
ADMA support price is $3.42 and resistance is $3.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADMA stock will trade within this expected range on the day.